Jean-Christophe Brisset1, Stefanie Galbn2, Alnawaz Rehemtulla2, Kenneth James Pienta3, Craig J. Galbn1, Brian Dale Ross1
1Radiology, University of Michigan, Ann Arbor, MI, United States; 2Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States; 3Department of Internal Medicine & Urology, University of Michigan, Ann Arbor, MI, United States
Bone metastases occur in more than 90% of patients with advanced prostate cancer. The purpose of this study was to develop an imaging biomarker to monitoring a patients' individual therapeutic progress. Human prostate cancer cells were implanted by direct intra-tibial injection into mice. Control (N=6), docetaxel (qd7x3; N=5), Radiation therapy (2 Gy/day 5x per week, 2 weeks; N=7) and combined treatment (N=5) were performed. DW-MRI was performed the first 2 weeks. Our results demonstrate the potential of quantitative ADC map for assessing tumor response even at the early time post therapy.